5-HT2C receptor agonists as an innovative approach for psychiatric disorders

Drug News and Perspectives

Volumn 20, Issue 9, 2007, Pages 565-571

  Rosenzweig Lipson, Sharon ^a   Dunlop, John ^a   Marquis, Karen L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 PYRIDYL)UREA; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL] 6 TRIFLUOROMETHYLINDOLINE; AGOMELATINE; ARIPIPRAZOLE; CLOZAPINE; CP 80910; DIZOCILPINE; FLUOXETINE; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; ORG 12962; SCA 136; SEROTONIN 2C AGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; UNCLASSIFIED DRUG; VABICASERIN; WAY 161503; WAY 163909; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

CATALEPSY; DEPRESSION; DIABETOGENESIS; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MENTAL DISEASE; MOOD DISORDER; NEUROTRANSMISSION; NONHUMAN; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ANIMAL; DRUG DESIGN; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; DEPRESSIVE DISORDER; DRUG DESIGN; HUMANS; RECEPTOR, SEROTONIN, 5-HT2C; SCHIZOPHRENIA; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SIGNAL TRANSDUCTION;

EID: 41649109395     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2007.20.9.1162244     Document Type: Review

References (68)

1. Berg, K.A., Maayany, S. Goldfarb, J and Clarke, W.P. Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists. Ann N Y Acad Sci 1998, 861: 104-10.
2. Kenakin, T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 1995, 16(7): 232-8.
3. Niswender, C.M., Sanders-Bush, E. and Emeson, R.B. Identification and characterization of RNA editing events within the 5-HT2C receptor. Ann N Y Acad Sci 1998, 861: 38-48.
4. Herrick-Davis, K., Grinde, E. and Teitler, M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 2000, 295(1): 226-32.
5. Rauser, L., Savege, J.E., Meltzer, H.I. and Roth, B.L. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine 2C receptor. J Pharmacol Exp Ther 2001, 299(1): 83-9.
6. Zhang, J.Y., Kowal, D.M., Nawoschik, S.P., Lou, Z. and Dunlop, J. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol 2006, 71(4): 521-9.
7. Berg, K.A., Cropper, J.D., Niswender, C.M., Sanders-Bush, E., Emeson, R.B. and Clarke, W.P. RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity. Br J Pharmacol 2001, 134(2): 386-92.
8. Sodhi, M.S., Burnet, P.W., Makoff, A.J., Kerwin, R.V. and Harrison, P.J. RNA editing of the 5-HT(2C) receptor is reduced in schizophrenia. Mol Psychiatry 2001, 6(4): 373-9.
9. Niswender, C.M., Herrick-Davis, K., Diller, G.E. et al. RNA editing of the human serotonin 5-HT2C receptor, alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology 2001, 24(5): 478-91.
10. Dracheva, S., Elhakem, S.L., Marcus, S.M., Siever, L.J., McGurk, S.R. and Haroutunian, V. RNA editing and alternative splicing of human serotonin 2C receptor in schizophrenia. J Neurochem 2003, 87(6): 1402-12.
11. Gurevich, I., Englander,, M.T., Adlesberg, M.T., Siegal, N.B. and Schmauss, C. Modulation of serotonin 2C receptor editing by sustained changes in serotonergic neurotransmission. J Neurosci 2002, 22(24): 10529-32.
12. Iwamoto, K. and Kato, T. RNA editing of serotonin 2C receptor in human postmortem brains of major mental disorders. Neurosci Lett 2003, 346(3): 169-72.
13. Scriabine, A. Psychiatric drug discovery and development, Princeton, NJ, USA, June 23-24, 2003. CNS Drug Rev 2003, 9(3): 319-26.
14. Siuciak, J.A., Chapin, D.S., McCarthy, S.A. et al. CP-809,101, a selective 5-HT(2C) agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 2007, 52(2): 279-90.
15. Rosenzweig-Lipson, S. et al. Antipsychotic-like effects of the 5-HT2C selective agonist WAY-163909 in rodents. Fundamental Clin Pharmacol 2004, 18: 145.
16. Dunlop, J.,, Saab, A.L., Mazandarani, H. et al. WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10, 10a-octahydro-7bH-cyclopenta-[b][1,4]-diazepino[6,7,1hi] indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J Pharmacol Exp Ther 2005, 313(2): 862-9.
17. Rosenzweig-Lipson, S. et al. Pharmacological characterization of the novel 5-HT2C agonist SCA-136: Antidepressant-like effects. Neuropsychopharmacology 2005, 29(Suppl. 1): S188.
18. Miyamoto, S., Duncan, G.E., Marx, C.E. and Lieberman, J.A. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005, 10(1): 79-104.
19. Wood, M.D., Scott, C., Clarke, K. et al. Pharmacological profile of antipsychotics at monoamine receptors: Atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets 2006, 5(4): 445-52.
20. Gobert, A., Rivet, J.M., Lejeune, F. et al. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat. Synapse 2000, 36(3): 205-21.
21. Di Matteo, V., Di Gionavvi, G., Di Mascio, M. and Esposito, E. Selective blockade of serotonin2C/2B receptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacology 1998, 37(2): 265-72.
22. Shilliam, C.S. and Dawson, L.A. The effect of clozapine on extracellular dopamine levels in the shell subregion of the rat nucleus accumbens is reversed following chronic administration: Comparison with a selective 5-HT2C receptor antagonist. Neuropsychopharmacolgy 2005, 30(2): 372-80.
23. Blackburn, T.P., Minabe, Y., Middlemiss, D.N., Shirayama, Y., Hashimoto, K. and Ashby, C.R. Jr. Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: An in vivo extracellular single cell study. Synapse 2002, 46(3): 129-39.
24. Blackburn, T.P., Suzuki, K. and Ashby, C.R. Jr. The acute and chronic administration of the 5-HT(2B/2C) receptor antagonist SB-200646A significantly alters the activity of spontaneously active midbrain dopamine neurons in the rat: An in vivo extracellular single cell study. Synapse 2006, 59(8): 502-12.
25. Di Matteo, V., Di Gionanni, G., Di Mascio, M. and Esposito, E. SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 1999, 38(8): 1195-205.
26. Di Giovanni, G., Di Matteo, V., Di Mascio, M. and Esposito, E. Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse 2000, 35(1): 53-61.
27. 2C receptor agonist possessing atypical antipsychotic-like effects in preclinical models. 36th Annu Meet Soc Neurosci (Oct 14-18, Atlanta) 2006, Abst 93.4.
28. Marquis, K.L., Sabb, A.L., Loque, S.F. et al. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino-[6,7, 1hi]indole]': A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 2007, 320(1): 486-96.
29. Di Giovanni, G., De Deurwaerdére, P., Di Mascio, Di Matteo, V., Esposito, E. and pampinato, U. Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: A combined in vivo electrophysiological and microdialysis study. Neuroscience 1999, 91(2): 587-97.
30. Ellenbroek, B.A. Pre-attentive processing and schizophrenia: Animal studies. Psychopharmacology (Berl) 2004, 174(1): 65-74.
31. Rosenzweig-Lipson, S. et al. Vabicaserin: Effects of a novel 5-HT2C agonist on prefrontal cortical neurotransmission, cognition and sensorimotor gating. 20th Cong Eur Coll Neuropsychopharmacol (ECNP) (Oct 13-17, Vienna) 2007, Abst P.3.d.019.
32. Marquis, K.L., Sabb, A.L., Loque, S.F et al. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino-[6,7, 1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 2007, 320(1): 486-96.
33. Chagnon, Y.C. Susceptibility genes for the side effect of antipsychotics on body weight and obesity. Curr Drug Targets 2006, 7(12): 1681-95.
34. Bickerdike, M.J. 5-HT2C receptor agonists as potential drugs for the treatment of obesity. Curr Top Med Chem 2003, 3(8): 885-97.
35. Chaput, Y., de Montigny, C. and Blier, P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: Electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1986, 333(4): 342-8.
36. Invernizzi, R., Bramante, M. and Samanin, R. Role of 5-HT1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacol Biochem Behav 1996, 54(1): 143-7.
37. Dawson, L.A., Nguyen, H.K., Smith, D.I. and Schechter, L.E. Effects of chronic fluoxetine treatment in the presence and absence of (±)pindolol: A microdialysis study. Br J Pharmacol 2000, 130(4): 797-804.
38. Beyer, C.E., Boikess, S., Luo, B. and Dawson, L.A. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: An in-vivo microdialysis study. J Psychopharmacol 2002, 16(4): 297-304.
39. Cryan, J.F. and Lucki, I. Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors. J Pharmacol Exp Ther 2000, 295(3): 1120-6.
40. Rosenzweig-Lipson, S. et al. WAY-163909, a 5-HT2C selective agonist for the treatment of obesity, depression and schizophrenia: Lack of tolerance. 35th Annu Meet Soc Neurosci (Nov 12-16, Washington, D.C.) 2005, Abst 914.7.
41. Rosenzweig-Lipson, S., Sabb, A., Stack, G. et al. Antidepressant-like effects of the novel, selective, 5-HT(2C) receptor agonist WAY-163909 in rodents. Psychopharmacology 2007, 192(2): 159-70.
42. Martin, J.R., Boss, M., Jenck, F. et al. 5-HT2C receptor agonists: Pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 1998, 286(2): 913-24.
43. Mitchell, P. and Redfern, P. Effects of m-chlorophenylpiperazine and mesulergine on rodent agonistic behaviour. J Psychopharmacol 2000, 14: A32 (PD2).
44. Mitchell, P.J. and Redfern, P.H. Animal models of depressive illness: The importance of chronic drug treatment. Curr Pharm Des 2005, 11(2): 171-203.
45. Marsden, C.A. and Stanford, S.C. CNS drugs III: Psychotherapeutics. Expert Opin Investig Drugs 2000, 9(8): 1923-9.
46. Moreau, J.L., Jenck, F., Martin, J.R., Perrin, S. and Hefely, W.E. Effects of repeated mild stress and two antidepressant treatments on the behavioral response to 5-HT1C receptor activation in rats. Psychopharmacology (Berl) 1993, 110(1-2): 140-4.
47. Moreau, J.L., Bös, M., Jenck, F., Martin, J.R., Mortas, P. and Wichmann, J. 5-HT2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. Eur Neuropsychopharmacol 1996, 6(3): 169-75.
48. Sukoff Rizzo, S.J., Schechter, L.E. and Rosenzweig-Lipson, S. A novel approach for predicting antidepressant-induced sexual dysfunction in rats. Psychopharmacology 2008, 195(4): 459-67.
49. Akiyoshi, J., Isoqawa, K, Yamada, K., Nagayama, H. and Fujii, I. Effects of antidepressants on intracellular Ca2+ mobilization in CHO cells transfected with the human 5-HT2C receptors. Biol Psychiatry 1996, 39(12): 1000-8.
50. Mitchell, P.J., Fairhal, S.J., Fletcher, A. and Redfern, P.H. Effects of single and repeated electroconvulsive shock on the social and agonistic behaviour of resident rats.[erratum appears in Neuropharmacology. 2004 Mar, 46(4): 607]. Neuropharmacology 2003, 44(7): 911-25.
51. Dremencov, E., Weizmann, Y., Kinor, N., Gispan-Herman, I. and Yadid, G. Modulation of dopamine transmission by 5-HT2C and 5-T3 receptors: A role in the antidepressant response. Curr Drug Targets 2006, 7(2): 165-75.
52. Millan, M.J. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: Focus on novel therapeutic strategies. Therapie 2005, 60(5): 441-60.
53. Jenck, F. et al. Brain 5-HT1C receptors and antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 1994, 18(3): 563-74.
54. Sanchez, C. and Hyttel, J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999, 19(4): 467-89.
55. Marcoli, M. et al. Trazodone is a potent agonist at 5-HT2C receptors mediating inhibition of the N-methyl-D-aspartate/nitric oxide/cyclic GMP pathway in rat cerebellum. J Pharmacol Exp Ther 1998, 285(3): 983-6.
56. Franklin, M. Determination of nefazodone and its metabolites in plasma by high-performance liquid chromatography with coulometric detection. J Pharm Biomed Anal 1993, 11(11-12): 1109-13.
57. Caccia, S. et al. Determination of plasma and brain concentrations of trazodone and its metabolite, 1-m-chlorophenylpiperazine, by gas-liquid chromatography. J Chromatogr 1981, 210(2): 311-8.
58. von Moltke, L.L., Greenblatt, D.J. Granda, B.W., Grassi, J.M., Schmider, J., Armatz, J.S. and Shader, R.I. Nefazodone, metachlorophenylpiperazine, and their metabolites in vitro: Cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology 1999, 145(1): 113-22.
59. Maes, M. et al. Effects of trazodone and fluoxetine in the treatment of major depression: Therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine. J Clin Psychopharmacol 1997, 17(5): 358-64.
60. Millan, M.J., Gobert, A., Lejeune, F. et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003, 306(3): 954-64.
61. Overstreet, D.H., Pucilowski, O., Retton, M.C., Delagrande, P. and Guardiola-Lamaire, B. Effects of melatonin receptor ligands on swim test immobility. Neuroreport 1998, 9(2): 249-53.
62. Hill, M.N., Brotto, L.A., Lee, T.T. and Golzarlka, B.B. Corticosterone attenuates the antidepressant-like effects elicited by melatonin in the forced swim test in both male and female rats. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27(6): 905-11.
63. Micale, V., Arezzi, A., Rampello, L. and Drago, F. Melatonin affects the immobility time of rats in the forced swim test: the role of serotonin neurotransmission. Eur Neuropsychopharmacol 2006, 16(7): 538-45.
64. Ergun, Y., Ergun, U.G., Orhan, F.O. and Kuçuk, E. Co-administration of a nitric oxide synthase inhibitor and melatonin exerts an additive antidepressant-like effect in the mouse forced swim test. Med Sci Monit 2006, 12(9): BR307-12.
65. Cremers, T.I., Giorgetti, M., Npsker, F.J. et al. Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin reuptake blockade. Neuropsychopharmacology 2004, 29(10): 1782-9.
66. Yamada, J. and Sugimoto, Y. Effects of 5-HT2 receptor antagonists on the anti-immobility effects of imipramine in the forced swimming test with mice. Eur J Pharmacol 2001, 427: 221-5.
67. Clenet, F., De Vos, A. and Bourin, M. Involvement of 5-HT(2C) receptors in the anti-immobility effects of antidepressants in the forced swimming test in mice. Eur Neuropsychopharmacol 2001, 11(2): 145-52.
68. Landen, M. and Thase, M.E. A model to explain the therapeutic effects of serotonin reuptake inhibitors: The role of 5-HT2 receptors. Psychopharmacol Bull 2006, 39(1): 147-66.